111 related articles for article (PubMed ID: 7993073)
1. Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1.
Moog C; Wick A; Le Ber P; Kirn A; Aubertin AM
Antiviral Res; 1994 Aug; 24(4):275-88. PubMed ID: 7993073
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus.
Debyser Z; De Vreese K; Pauwels R; Yamamoto N; Anné J; De Clercq E; Desmyter J
J Gen Virol; 1992 Jul; 73 ( Pt 7)():1799-804. PubMed ID: 1378481
[TBL] [Abstract][Full Text] [Related]
3. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
Pauwels R; Andries K; Debyser Z; Kukla MJ; Schols D; Breslin HJ; Woestenborghs R; Desmyter J; Janssen MA; De Clercq E
Antimicrob Agents Chemother; 1994 Dec; 38(12):2863-70. PubMed ID: 7535037
[TBL] [Abstract][Full Text] [Related]
4. Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.
Buckheit RW; Germany-Decker J; Hollingshead MG; Allen LB; Shannon WM; Janssen PA; Chirigos MA
AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1097-106. PubMed ID: 7508723
[TBL] [Abstract][Full Text] [Related]
5. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.
Debyser Z; Pauwels R; Andries K; Desmyter J; Kukla M; Janssen PA; De Clercq E
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1451-5. PubMed ID: 1705038
[TBL] [Abstract][Full Text] [Related]
6. TIBO derivatives: a new class of highly potent and specific inhibitors of HIV-1 replication.
Pauwels R; Andries K; Debyser Z; Kukla M; Schols D; Desmyter J; De Clercq E; Janssen PA
Biochem Soc Trans; 1992 May; 20(2):509-12. PubMed ID: 1383063
[No Abstract] [Full Text] [Related]
7. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
Pauwels R; Andries K; Desmyter J; Schols D; Kukla MJ; Breslin HJ; Raeymaeckers A; Van Gelder J; Woestenborghs R; Heykants J
Nature; 1990 Feb; 343(6257):470-4. PubMed ID: 1689015
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of the acquired immune deficiency syndrome (AIDS): non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase.
De Clercq E
Int J Immunopharmacol; 1991; 13 Suppl 1():83-9. PubMed ID: 1726686
[TBL] [Abstract][Full Text] [Related]
9. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
[TBL] [Abstract][Full Text] [Related]
11. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
12. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
[TBL] [Abstract][Full Text] [Related]
14. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
17. Derivatives of 4-amino-3,6-disulfonato-1,8-naphthalimide inhibit reverse transcriptase and suppress human and feline immunodeficiency virus expression in cultured cells.
Rideout D; Schinazi R; Pauza CD; Lovelace K; Chiang LC; Calogeropoulou T; McCarthy M; Elder JH
J Cell Biochem; 1993 Apr; 51(4):446-57. PubMed ID: 7684385
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
[TBL] [Abstract][Full Text] [Related]
19. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
Merluzzi VJ; Hargrave KD; Labadia M; Grozinger K; Skoog M; Wu JC; Shih CK; Eckner K; Hattox S; Adams J
Science; 1990 Dec; 250(4986):1411-3. PubMed ID: 1701568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
